ONCOVIR, INC.

Biotech · Private

Hiltonol (poly-ICLC), a stabilized double-stranded RNA immunotherapeutic molecule that activates innate and adaptive immunity for intratumoral cancer treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Total capital: $1.5M

Federal grants: $1.5M; 2 awards · 2016–2017; Rank in peer group#193 of 326
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 6 pending

Capital timeline

Latest events

Aug 2017Federal grantHealth and Human S · Phase II · In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study$732K
Sep 2016Federal grantHealth and Human S · Phase II · In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study$732K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 326 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 6

Mar 20, 2025PendingOptimized Multidimensional Biological Activity Of Poly-iclc With Controlled Component Size And FormulationUSPTOApplication 18445640
Mar 20, 2025PendingMethod for Prophylaxis and Attenuation of COVID19 and other Inflammatory Microbial Acute Respiratory Disease Syndromes through Modulation of Innate and Adaptive Immunity with Poly ICLCUSPTOApplication 18445641
Aug 8, 2024PendingScalable Production Of Polyribonucleotides Of Controlled SizeUSPTOApplication 17803950

Show all 6 patent records

Optimized Multidimensional Biological Activity Of Poly-iclc With Controlled Component Size And FormulationMar 20, 2025 · Application 18445640Pending
Method for Prophylaxis and Attenuation of COVID19 and other Inflammatory Microbial Acute Respiratory Disease Syndromes through Modulation of Innate and Adaptive Immunity with Poly ICLCMar 20, 2025 · Application 18445641Pending
Scalable Production Of Polyribonucleotides Of Controlled SizeAug 8, 2024 · Application 17803950Pending
Optimized Multidimensional Biological Activity Of Poly-iclc With Controlled Component Size And FormulationApplication PCTUS2022000015Pending
Method For Prophylaxis And Attenuation Of COVID-19 And Other Inflammatory Microbial Acute Respiratory Disease Syndromes Through Modulation Of Innate And Adaptive Immunity With Poly- IclcApplication PCTUS2022000012Pending
Scalable Production Of Polyribonucleotides Of Controlled SizeApplication PCTUS2021010032Pending

Charlesson, LLCSimilar federal contract value in Biotech · null in contracts
Blue Sky Pharmaceuticals, LLCSimilar federal contract value in Biotech · null in contracts
JUPITER NEUROSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
THERATROPHIX, LLCSimilar federal contract value in Biotech · null in contracts
ELEVEN THERAPEUTICS CORPSimilar federal contract value in Biotech · null in contracts
AviadoBioSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.